Lead Criteria. Prior to the Threshold Date, and before Infinity commences screening a Target (or when a Target is identified as set forth in 3.1.2(b)(ii)), the Joint Steering Committee shall determine, pursuant to Section 2.3.2(d), the appropriate assays and criteria (the “Lead Criteria”) that will trigger Novartis’ Option with respect to such Lead Program comprised of one or more Lead Series, such Lead Criteria to include at least the following:
Appears in 4 contracts
Samples: Collaboration and Option Agreement, Collaboration and Option Agreement (Discovery Partners International Inc), Collaboration and Option Agreement (Infinity Pharmaceuticals, Inc.)
